The eIACUC system for submission of Animal Protocols is required for all projects utilizing a vertebrate animal species.
NOTE: A PI can choose to authorize other personnel to access, edit/amend, and start new Animal Protocols in his/her name, by utilizing the Authorizations Manager. See Managing Authorizations [2] for more information.
Training is available:
The Office of the IACUC has provided a pdf User Guide [3] to assist labs in utilizing the system. Please contact the Office of the IACUC at iacuc@uiowa.edu [4] to schedule training, and/or with any questions regarding use of the system.
Specific Help Materials for the eIACUC Animal Protocol Management System can be found at the following links:
We have made every effort to create a user-friendly updated form to collect the information in our new eIACUC system.
As a result, some of the questions you are accustomed to seeing in the Word document form may have changed, or the information described will be collected in a different place. Please read each question carefully prior to answering, as familiar questions may have changed.
In an effort to ease the transition to the new form, the eIACUC Team has assembled a table which matches each new question in the eIACUC form with the location in the previous Animal Protocol form where this information might be found. It will also indicate which questions are new in the eIACUC form, which will hopefully minimize any confusion in searching for the answer to an updated question in a previous template.
eIACUC Section/Question |
|
Location in Old Animal Protocol Form |
Project Information |
||
Type of Protocol |
|
IV. Type of project |
If renewal, Previous Animal Protocol # |
|
IV. Type of project |
IF duplicate, Original Animal Protocol # |
|
IV. Type of project |
Project Title |
|
II. Project Information |
Project Start Date |
|
II. Project Information |
Is this an Overall Protocol? |
|
This is a New Question |
Is this a Training Grant? |
|
IV. Type of project |
Is this a Center or Program Project? |
|
IV. Type of project |
Species |
|
#5 Animal Information |
Internal Funding |
|
III. Funding Information |
External Funding |
|
III. Funding Information |
Funding Source |
|
III. Funding Information |
Funding Agency Number |
|
III. Funding Information |
Is this NIH funding? |
|
III. Funding Information |
Is this grant subcontracted through another institution? |
|
This is a New Question |
|
|
|
Principal Investigator |
||
Principal Investigator Search |
|
I. Principal Investigator |
Is a Co-Principal Investigator involved in this protocol? |
|
I. Co-Investigators and #4 Co-Investigators |
Are Technical/Student Personnel involved in this protocol? |
|
#4 Technical Personnel |
|
|
|
Co-Principal Investigator |
||
Co-Principal Investigator Search |
|
I. Co-Investigator |
|
|
#4 Principal Investigator/ Co-Investigators |
|
|
|
Technical/Student Personnel |
||
Technical/Student Personnel Search |
|
#4 Technical Personnel |
|
|
|
Rationale and Purpose of Animal Use |
||
The aims and objectives of this project including long term goals. (The grant abstract may not be used.) |
|
#1 The aims and objectives of this project including long term goals |
Briefly explain the relevance this work will have to human or animal health, the advancement of knowledge, or the good of society. |
|
#1 The aims and objectives of this project including long term goals |
Will animals in this project be used in an instructional course? |
|
V. Special Concerns |
|
|
|
Consideration of Alternatives |
||
Was a literature search performed? |
|
#2 Questions specifically mandated by regulations |
If Yes: |
|
|
Database(s) Searched |
|
#2.a You must perform a databse search… |
Date Search Performed |
|
#2.a You must perform a databse search… |
Year Began Search |
|
#2.a You must perform a databse search… |
Year Ended Search |
|
#2.a You must perform a databse search… |
Search terms. The phrase "animal testing alternatives" must be one of the phrases paired with all potentially painful or distressing procedures. |
|
#2.a You must perform a databse search… |
Were any alternatives identified by the literature search |
|
#2.c Comment upon the potential application of any identified alternatives |
If No: |
|
|
Provide a narrative to explain how it was determined that no acceptable animal testing alternatives are available. |
|
#2.b If a literature serach is NOT performed, provide a narrative to justify why this project is not duplicative and that no acceptable alternatives are available |
Reduction in number of animals required |
|
#2.d Describe what consideration has been given to the following alternatives: Reducing the number of animals required |
Replacement of vertebrate species with non-mammalian or invertebrate species |
|
#2.d Describe what consideration has been given to the following alternatives: Use of a non-mammalian or invertebrate species |
Refinement of procedure(s) to lessen or eliminate pain or distress to the animal |
|
#2.d Describe what consideration has been given to the following alternatives: Modifying a procedure to lessen or eliminate pain or distress to the animal |
Use of a non-animal system (cell or tissue culture, computer or mathematical model, etc) |
|
#2.d Describe what consideration has been given to the following alternatives: use of a non-animal system |
|
|
|
Animal Information |
||
Describe the characteristics of this species which make it essential to the proposed study |
|
#5 Animal Information |
Animal Housing Location |
|
#8 Animal Housing Location |
Animal Numbers |
|
#6a. Approximately how many of each species will be used |
Justification of Animal Numbers |
|
#6b.Describe how the number of nimals needed for the study was determined |
Does the phenotype of any animals used result in adverse effects, distress or pain? |
|
#6e. Does expression of the transgene/knockout phenotype result in pain/distress? |
If Yes: |
|
|
Describe how any adverse effects, distress, or pain related to the phenotype(s) will be humanely managed, including clinical signs which would result in supportive care and/or veterinary consultation. Include criteria for euthanasia if applicable |
|
#23 Are there any predictable adverse pre- or poest-procedural events that may occur |
Will non-naïve animals be used on this Animal Protocol? Examples include surgically-altered animals obtained from a vendor or animals used on another Animal Protocol (including procedures such as genotyping). |
|
#7 Will the animals used in this study be subjected to any of the following: The animal(s) utlized in this study will have already been used in a previous study (non-naïve animals) |
|
|
|
Experimental Design |
||
Provide a succinct timeline of all procedures which may be performed on each animal/group, from the start of the study until the experimental endpoint (e.g. euthanasia). Include relevant information for each experimental group, such that it is clear what will happen to any given animal. |
|
This is a new field. Some information may have previously been included in Question #27. |
|
|
|
Non-surgical Procedures |
||
Will tissues be collected for identification and/or genetic analysis? |
|
#17 Are tissues collected before euthanasia? |
Will blood samples be collected for any reason? |
|
#21 Will antemortem blood samples be taken? |
Will any agent(s) be administered for experimental use? (Exclude anesthetics and analgesics) |
|
This information was previously included under #27 |
Will food and/or water be restricted? |
|
#24 Will food and/or water be restricted? |
Will any special husbandry or housing conditions be required for this project? (check all that apply) |
|
# 10 Will any special housing conditions be required for this project (lighting, feed, special caging, biological containment, etc.)? |
Will animals be kept outside of the OAR animal facilities for longer than 24 consecutive hours? |
|
#9 Will animals be kept outside of the OAR animal quarters for longer than 12 or 24 hours |
Will animals be restrained by methods other than brief manual restraint? |
|
#25 Will animals be restrained by tethers, stanchions, metabolism cages, etc.? |
Will additional non-surgical procedures be performed? |
|
This information was previously included under #27 |
|
|
|
Surgery |
||
Will Survival Surgery be performed? |
|
#26 Will Survival surgery be performed? |
Surgical Description |
|
This information was previously included under #27 |
Describe the immediate post-anesthesia recovery care (e.g. fluids, physical support methods), including the monitoring schedule until fully ambulatory. |
|
#26.c Describe the postoperative care, fluids, physical support methods and postoperative monitoring given to the animals |
Describe post-surgical animal monitoring to be performed by laboratory personnel until incision closures are removed |
|
#23 Are there predictable adverse pre- or post-procedural events that may occur? |
Will multiple survival surgeries be performed on the same animal? |
|
#26.a Will "multiple" survival surgeries be peformed on the same animal? |
How are the instruments sterilized? |
|
#26.e "How are the instruments sterilized? |
How do you confirm that proper sterilization has occurred? |
|
#26.f How do you insure that proper sterilization has occurred? |
Minimum Surgical Garb |
|
#26.g Does the surgeon utilize the following during surgery? |
Will non-survival surgery be performed? |
|
This information was previously included under #27 |
|
|
|
Analgesia |
||
Will any non-surgical OR surgical procedure(s) be performed that may potentially cause more than momentary pain or distress? |
|
#22 Is any procedure (including survival surgery) likely to cause pain or distress? |
|
|
|
Anesthesia |
||
Will anesthesia be administered? Please refer to Anesthesia Guidelines for routinely used anesthetic agents and dosages. |
|
#19 b Anesthetic agent(s), dosage and route |
Will any euthanasia procedure(s) be performed under anesthesia? |
|
This is a New Question |
Maximum number of times this anesthetic protocol will be used (per animal). |
|
#19.d How many times will anesthesia be required for each animal during the study |
Describe how this anesthesia will be maintained, if applicable |
|
#19.c For prolonged procedures how will anesthesia be maintained? |
Indicate the methods used to monitor the level of anesthesia and animal’s well-being. At least two methods must be used during any procedure. |
|
#19.e Describe the methods used to monitor the state of anesthesia and general wellbeing |
Will paralytic agents be employed? |
|
#19.f Will paralytic agents be employed? |
|
|
|
Endpoints & Euthanasia |
||
Will any studies be conducted where death is an expected endpoint (e.g., death due to septicemia)? |
|
Part V. Will any studies be conducted where death is an expected endpoint (e.g., death due to septicemia)? |
Will all animals utilized in this protocol be euthanized as part of the planned studies? |
|
#16 a. Describe fully the method of euthanasia that will be employed for each species |
|
|
|
Special Circumstances & Hazards |
||
Will custom antibodies be produced for these studies? |
|
V. Custom antibody production |
Does this study utilize nucleic acid molecules in vivo AND are the animals returned to the OAR after exposure? |
|
#14 Does this study utilize rDNA in vivo AND the animals are returned to the Animal Care Unit after exposure? |
Will this Animal Protocol involve the use or breeding of genetically engineered animals? |
|
#6, #14 |
Will the project involve stem cells? |
|
#15 Are any of the substances listed in 15.a. used in this project? |
Will any radioactive materials be used in this Animal Protocol? |
|
#15 Are any of the substances listed in 15.a. used in this project? |
Are any [hazardous] substances listed below used in this project? |
|
#15.a Specify the hazardous substance |
Do any of the hazardous substances listed above require special handling, such as ABSL-2 or ABSL-3 handling precautions or yellow “Hazardous Agent” cards? |
|
#15b Containment/#10 Special housing ABSL |
If Yes: |
|
|
Are any of these substances introduced into animals that are returned to the OAR facilities ALIVE? |
|
#15.b Are any of the substances listed in 15.a introduced into animals that are returned to the Animal Care Unit ALIVE? |
Could any of the hazardous substances listed above contaminate animal caging? |
|
#15.e Could any of the hazardous substances listed in 15.a contaminate Animal Caging? |
For full detailed directions of the eIACUC Program, please see the eIACUC User Guide [3].
To view, download, and/or print the eIACUC User Guide, click here: eIACUC User Guide.pdf [5]
A PI can choose to authorize other personnel to access, edit/amend, and start new Animal Protocols in his/her name, by utilizing the Authorizations Manager.
The PI can also choose to grant one or more individual(s) permissions to make authorizations to other personnel. This permission level allows the authorized individual to perform many tasks on the PI’s behalf; however, the PI remains ultimately responsible for all activity performed under the Animal Protocol.
To adjust the access level of any person listed on your Animal Protocol (or grant access to an individual not listed as personnel on your Animal Protocol), click the “Go to Authorizations Manager” button at the top of the Authorizations Summary page.
There are four access levels that can be selected:
All personnel listed on one (or more) of your existing Animal Protocol(s) will be initially granted “View Only” access to the Animal Protocol(s) on which they are listed.
How do I log out of eIACUC?
Because eIACUC provides access to multiple systems using a single login, you will need to end your session by closing your browser. This will ensure that anyone that uses your computer will not automatically be logged in as you when they use your browser to go to research administration websites.
Note: Logging out of other research administration sites may disrupt your single sign-on experience.
The eIACUC system allows you to sign-on to one site and navigate between research administration sites without logging on again. Logging out of other research administration sites will end your session on on that site but not on other research sites such as eIACUC. If you have a window open to UIRIS, HawkIRB, or other sites you reached via the portal you will continue to be able to use them, but clicking on a link to the site you logged off of will require you to log in. Always close your browser when ending a session with your research administration sites.
A blank form can be found here:
Agent Administration Table Template.xlsx [6]
Example (Filled) Agent Administration Table can be viewed here:
Each group of animals will undergo surgery to place a minipump subcutaneously. Some of these animals will also have an intracerebral cannula connected to the minipump for drug delivery, while the others will have the drug delivered subcutaneously. After two to eight weeks of drug administration, groups may begin behavioral studies (procedure A, B, C, or D), which may occur as frequently as daily for up to 4 weeks, or twice weekly for up to 6 months. Some animals may undergo a second surgical procedure to replace the minipump after 4 weeks of delivery, to provide a total of 8 weeks of continuous drug administration. Some animals will be euthanized at intervals after drug delivery without further testing, while others will be euthanized following behavioral testing of up to 6 months. The maximum time from the start of studies to euthanasia will be 8 months.
Each group of animals will be administered drugs by various routes over the course of up to 3 months (see drug table). Following at least one week of drug administration, blood pressure samples will be collected using noninvasive methods. Once the drug administration period is completed (up to 3 months after starting), some animals will undergo a non-survival surgery procedure for surgical blood pressure sampling procedures at various times after the last drug dose. Other groups will be euthanized and tissues collected for further analysis. Time from start of drug administration to euthanasia will be no more than 1 year.
Project 1) Groups of animals will be inoculated with 5 different doses of Example Virus or vehicle, with or without the addition of Example Drug A, B, or C at the time of injection. After appearance of clinical disease, some animals will receive treatment with experimental agents D, E, F, or G over the course of up to 12 weeks. Other animals will receive vehicle alone or no treatment. At time points up to 24 weeks after initial inoculation, animals will be euthanized and tissues collected.
Project 2) Animals will undergo one of 4 surgical procedures (Procedure A, B, C, or D) followed by treatment with Example Drug A, B, or C at the time of surgery. Some animals will receive treatments with agents D, E, or F as detailed above, and euthanized at up to 2 years following initial surgery.
Project 3) Animals will be given medicated feed to induce gene expression for up to 10 weeks before inoculation with Example Virus with or without Example Drug A as described in Project 1. Over the following 6 weeks, clinical signs will be evaluated and animals euthanized at various time points for tissue analysis. Some animals will undergo non-survival procedure A to analyze immune reactions, after which they will be euthanized without recovery from anesthesia. Animals will be maintained for up to 15 months post-infection before euthanasia.
Animals will be purchased and euthanized for the postmortem collection of tissues. No other procedures will be performed.
Groups of animals will receive drug treatments by injection or in special feed for up to 8 weeks, after which they will be euthanized and tissues collected for further analysis.
E-mail: iacuc@uiowa.edu [4]
Phone: (319) 384-4773
Institutional Animal Care and Use Committee
L350 Pappajohn Biomedical Discovery Building (PBDB)
Iowa City, Iowa 52242-1181
Overall Project: When a large project grant gets funded, only a portion of it may involve animal work. The money may come into a University Center or an individual PI (i.e. main awardee) who has various PIs responsible for certain projects under the main grant. The main grant (encompassing all projects) is typically tied to what is called an “Overall” Animal Protocol approval. The Overall is a sort of landing-place for the grant, and does not outline any animal work. The specific projects involving animal work are tied to separate Animal Protocol approvals under the corresponding PIs.
Center/Program project: A grant for which there is a common theme (e.g. heart disease) but for which there are multiple projects that may be done by any number of Co-PIs under the main grant. The grant typically has a Primary awardee and comes into the University as a “Center/Program grant”. The grant will have a “P” such as P01, P20, etc in the grant ID number. The main grant (encompassing all projects) is typically tied to what is called an “Overall” Animal Protocol approval. The Overall is a sort of landing-place for the grant, and does not outline any animal work. The specific projects involving animal work are tied to separate Animal Protocol approvals under their corresponding PIs. The PIs involved in this type of grant, should refer to the Center/Program grant and the PI named as the primary PI (so that the funds can be appropriately followed back to the main grant).
Training Grant: A grant that geared to training students, post-docs, faculty, etc for which there is a common theme (e.g. heart disease). Only a portion of the grant may involve animal work. The money may come into a University Center and subsequently be distributed to the various PIs responsible for certain projects. The grant will have a “T” such as T32 in the grant ID number. The main grant (encompassing all projects) is typically tied to what is called an “Overall” Animal Protocol approval. The Overall is a sort of landing-place for the grant, and does not outline any animal work. The specific projects involving animal work are tied to separate Animal Protocol approvals under their corresponding PIs. The PIs involved in this type of grant, should refer to their protocol as a Training grant.
Anesthesia has been described as a series of four Stages.
Guidance for identification of hazardous substances used in projects
Some hazardous chemicals or drugs fall into multiple classifications/categories. List the substance in the category that, based on your review, fits best. You may specify multiple categories if appropriate. Include ALL substances that fit the categories below, regardless of containment status (inclusion in this list does not automatically require additional containment or special handling).
Human or non-human primate blood, blood products, tissues, tumors, and/or cells:
Include any cell, tissue, or blood product of human or non-human primate origin, including cells/tissues growing in culture.
Other animal blood, blood products, tissues, tumors, and/or cells:
Include any animal cell, tissue, or blood product which does not fall under the human or non-human primate category above.
Engineered Nanomaterials/Nanoparticles
Include any engineered nanomaterial/nanoparticle (size range 1-100 nanometers). Include the name of the material, the particle size/dimensions, and the form of the material administered to animals such as aerosol, liquid suspension, etc. Also include whether or not the materials is believed to be biodegradable. Limited examples include carbon nanotubes, titanium dioxide, polystyrene.
Toxic chemicals, including carcinogens
OSHA Hazard Classification | OSHA Hazard Category | OSHA Pictogram | Signal Word on Label or SDS | Hazard Statement on Label or SDS |
---|---|---|---|---|
Carcinogenicity | 1A, 1B | Danger | May cause cancer | |
Carcinogenicity | 2 | Warning | Suspected of causing cancer | |
Acute Toxicity, Oral | 1,2 | Danger | Fatal if swallowed | |
Acute Toxicity, Oral | 3 | Danger | Toxic if swallowed | |
Acute Toxicity, Dermal | 1,2 | Danger | Fatal in contact with skin | |
Acute Toxicity, Dermal | 3 | Danger | Toxic in contact with skin | |
Acute Toxicity, Inhalation | 1,2 | Danger | Fatal if inhaled | |
Acute Toxicity, Inhalation | 3 | Danger | Toxic if inhaled | |
Skin Corrosion/Irritation | 1A, 1B, 1C | Danger | Causes severe skin burns and eye damage | |
Eye Damage/Irritation | 1 | Danger | Causes serious eye damage | |
Sensitization, Respiratory | 1A, 1B | Danger | May cause allergy or asthma symptoms or breathing difficulties if inhaled | |
Sensitization, Skin | 1A, 1B | Warning | May cause an allergic skin reaction | |
Germ Cell Mutagenicity | 1A, 1B | Danger | May cause genetic defects | |
Specific Target Organ Toxicity, single exposure | 1 | Danger | Causes damage to organs (specific organs may be listed) | |
Specific Target Organ Toxicity, single exposure | 2 | Warning | May cause damage to organs (specific organs may be listed) | |
Specific Target Organ Toxicity, repeated exposure | 1 | Danger | Causes damage to organs though prolonged or repeated exposure | |
Aspiration hazard | 1 | Danger | May be fatal if swallowed and enters airways |
Limited examples include heavy metals, PCBs, neurotoxins, pesticides, benzene, DMBA, cyanide compounds, urethane, isocyanates
Examples may be found in the following references (carcinogenicity):
California Proposition 65 List of Chemicals (known to cause cancer or reproductive toxicity) [11]
National Toxicology Program (NTP), “Report on Carcinogens” (latest edition) [12]
International Agency for Research on Cancer (IARC), “Monographs on the Evaluation of Carcinogenic Risks to Humans” (latest editions) [13]
OSHA 29 CFR part 1910, Subpart Z, Toxic and Hazardous Substances
Hazardous drugs including chemotherapy/antineoplastic and investigational drugs
Using the NIOSH definition, drugs considered hazardous include those that exhibit one or more of the following six characteristics in humans or animals:
Examples may be found in the following references:
NIOSH publication NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2014 or most current [14]
OSHA Technical Manual “Controlling Occupational Exposure to Hazardous Drugs”
Appendix VI:2-1. Some Common Drugs Considered Hazardous [15]
OSHA Hazard Classification | OSHA Hazard Category | OSHA Pictogram | Signal Word on Label or SDS | Hazard Statement on Label or SDS |
---|---|---|---|---|
Carcinogenicity | 1A, 1B | Danger | May cause cancer | |
Carcinogenicity | 2 | Warning | Suspected of causing cancer |
Limited examples include doxorubicin, bleomycin sulfate, streptozotocin, cisplatin, tamoxifen, paclitaxel
Note that certain pharmaceuticals used in their common pharmaceutical form may be exempted at the discretion of the IACUC although they may have hazards such as carcinogenicity or reproductive hazards associated with their use.
Additional examples may be found in the following references:
National Toxicology Program (NTP), “Report on Carcinogens” (latest edition) [16]
International Agency for Research on Cancer (IARC), “Monographs on the Evaluation of Carcinogenic Risks to Humans” (latest editions) [17]
OSHA 29 CFR part 1910, Subpart Z, Toxic and Hazardous Substances
Reproductive hazards
Include mutagens, teratogens, developmental reproductive toxicity
OSHA Hazard Classification | OSHA Hazard Category | OSHA Pictogram | Signal Word on Label or SDS | Hazard Statement on Label or SDS |
---|---|---|---|---|
Germ Cell Mutagenicity | 1A, 1B | Danger | May cause genetic defects | |
Toxic to Reproduction | 1A, 1B | Danger | May damage fertility or the unborn child | |
Toxic to Reproduction | 2 | Warning | Suspected of damaging fertility or the unborn child |
Limited examples include BrdU, oxytetracycline hydrochloride, RU-486 (mifepristone), 5-FU (fluorouracil), ribavirin, bleomycin sulfate, tamoxifen citrate
Examples may be found in the following reference:
California Proposition 65 List of Chemicals (known to cause cancer or reproductive toxicity) [11]
Note that certain pharmaceuticals used in their common pharmaceutical form may be exempted at the discretion of the IACUC although they may have hazards such as carcinogenicity or reproductive hazards associated with their use.
Other potential or known hazardous substance (chemical)
Air-reactive, water-reactive, self-reactive other highly reactive chemicals with OSHA Signal Word “Danger”
Explosive chemicals with OSHA Signal Word “Danger”
Organic Peroxides with OSHA Signal Word “Danger”
Flammable Gases, Liquids, Aerosols, Solids with OSHA Signal Word “Danger”
Oxidizing Gases, Liquids, Solids with OSHA Signal Word “Danger”
Provide a brief summary of the purpose of the Animal Protocol amendment to be submitted. For example: "This amendment is needed to add 2 new procedures." or "This amendment is to increase animal numbers to achieve statistical significance following a pilot study, and to add additional personnel."
The procedures listed under Question #16 are populated from the "Non-surgical Procedures" and "Surgery" sections, respectively. Some procedures which are populated may not be those perceived to cause pain or distress. If a surgical or non-surgical procedure is not listed in Question #14, confirm that it has been entered under the appropriate section. If analgesia is to be administered for circumstances other than those populated in Question #14, describe it under Question #16.
The procedures listed under Question #12 are populated from the "Non-surgical Procedures" and "Surgery" sections, respectively. Some procedures which are populated may not be those perceived to cause pain or distress. If a surgical or non-surgical procedure is not listed in Question #10, confirm that it has been entered under the appropriate section. If anesthesia is to be administered for circumstances other than those populated in Question #10, describe it under Question #12.
For the purposes of euthanasia, rodents are grouped into 3 different age groups: fetus, neonate, and adult. The requirements for performance and/or confirmation of euthanasia procedures will depend upon the age of the animal. The age at which an animal moves from one group definition to another depends on the species.
Standard OAR housing (under either barrier or non-barrier conditions) is considered ABSL-1. These animals are treated with standard universal precautions; exposure to the animals and any agents which may be administered to them, is not known to cause disease in immunocompetent adult humans, and there is minimal potential hazard posed to personnel and the environment. This is in contrast to animals housed at ABSL-2, or -3, which are infected with agents capable of causing human or animal disease or are of unknown risk; these animals are handled with special measures, including procedures, equipment, and decontamination procedures, in order to control the risk of exposure. In the case of recombinant or synthetic nucleic acids, if you are unsure whether your rodents should be handled with increased containment measures, please contact the IBC at ehs-rdna@uiowa.edu [18] or 353-5679.
Clicking the "New Animal Protocol" button will create a new blank form to be completed for the purposes of describing animal research/teaching activities. Please see When is an Animal Protocol Required? [19] and/or contact the IACUC office at iacuc@uiowa.edu [4] if you need more information on the conditions which require an IACUC-approved Animal Protocol.
You may wish to locate an existing Animal Protocol for the purposes of viewing the Animal Protocol, creating an Amendment, renewing or copying the Animal Protocol, or editing a draft version. Animal Protocols may be located by entering one or more search terms in the appropriate box: Animal Protocol number, the PI name or the name of any personnel listed on the Animal Protocol, the Project Title (or portion thereof), and/or filter the Animal Protocols which you are authorized to view using any of the checkboxes or filter options available. Once you have entered the appropriate information, click the "Search" button to produce the Animal Protocol(s) which meet your criteria.
You may then select the appropriate Animal Protocol by clicking the blue Animal Protocol number on the left side of the table. Clicking this link will produce the Protocol Summary page, from which you may select subsequent actions (View, Edit, etc.)
The following are examples of how to adequately address experience for personnel included in the Animal Protocol.
(Non-surgical experience question) - For each species used, describe training and experience with Non -surgical techniques and procedures, or explain how he/she will be trained and by whom.
(Surgical experience question) - For each species used, describe training and experience with the proposed surgical procedure(s) or explain how he/she will be trained and by whom.
Training animals are used in cases where individuals need to develop skills and become competent in procedures, in addition to those used to refine a procedure. Includes an animal carcass or an animla used in a terminal/non-survival procedure.
Links:
[1] https://eiacuc.research.uiowa.edu/
[2] https://animal.research.uiowa.edu/managing-authorizations
[3] https://animal.research.uiowa.edu/eIACUCUserGuide
[4] mailto:iacuc@uiowa.edu
[5] https://animal.research.uiowa.edu/sites/animal.research.uiowa.edu/files/eIACUC%20User%20Guide_3.pdf
[6] https://animal.research.uiowa.edu/sites/animal.research.uiowa.edu/files/wysiwyg_uploads/Agent%20Administration%20Table%20Template_1.xlsx
[7] https://animal.research.uiowa.edu/sites/animal.research.uiowa.edu/files/Example%20Agent%20Administration%20Table.pdf
[8] http://guides.lib.uiowa.edu/animalalternatives
[9] http://www.nal.usda.gov/awic/alternatives/searches/altwksht.pdf
[10] http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-Laboratory-animals.pdf
[11] https://www.chemsafetypro.com/Topics/USA/California_Proposition_65_List.html
[12] http://ntp.niehs.nih.gov/pubhealth/roc/index-1.html
[13] http://monographs.iarc.fr/wp-content/uploads/2018/06/mono76.pdf
[14] https://www.cdc.gov/niosh/docs/2014-138/
[15] https://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html#app_VI:2_1
[16] https://ntp.niehs.nih.gov/pubhealth/roc/index-1.html
[17] https://monographs.iarc.fr/wp-content/uploads/2018/06/mono76.pdf
[18] mailto:ehs-rdna@uiowa.edu
[19] https://researchanimal.stage.drupal.uiowa.edu/animal-protocol#WhenAPRequired